These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760 [TBL] [Abstract][Full Text] [Related]
24. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119 [TBL] [Abstract][Full Text] [Related]
25. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520 [TBL] [Abstract][Full Text] [Related]
26. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A. Mazzio EA; Soliman KFA Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076 [TBL] [Abstract][Full Text] [Related]
33. Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines. Li H; Zhou S; Li X; Wang D; Wang Y; Zhou C; Schmid-Bindert G Cancer Biother Radiopharm; 2013 Mar; 28(2):115-23. PubMed ID: 23270470 [TBL] [Abstract][Full Text] [Related]
35. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. Kim M; Thompson LA; Wenger SD; O'Bryant CL Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522 [TBL] [Abstract][Full Text] [Related]
36. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells. Abutin RM; Chen J; Lung TK; Lloyd JA; Sawyer ST; Harada H Exp Hematol; 2009 Feb; 37(2):151-8. PubMed ID: 19100675 [TBL] [Abstract][Full Text] [Related]
37. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Hall CP; Reynolds CP; Kang MH Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839 [TBL] [Abstract][Full Text] [Related]
38. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma. Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073 [TBL] [Abstract][Full Text] [Related]
39. Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies. Makena MR; Koneru B; Nguyen TH; Kang MH; Reynolds CP Mol Cancer Ther; 2017 Apr; 16(4):649-661. PubMed ID: 28119491 [TBL] [Abstract][Full Text] [Related]
40. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]